Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan

• Status: Completed
• Trial end date: 2010-04-01

Summary

To evaluate the efficacy and safety of alogliptin administered as an add-on to sulfonylurea (glimepiride) or metformin, once daily (QD), twice daily (BID) or three times daily (TID).

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Takeda
• Treatments: Alogliptin; Glimepiride; Metformin